Browsing by Author "Arzu TATAR"

Now showing 1 - 2 of 2

Otoprotective effects of farnesene against oxidative damage induced by paclitaxel
(2022-03-01) Arzu TATAR; Büşra DİNÇER; Fatma ATALAY
Purpose: This study explores the biochemical and functional effects of farnesene, which has potent free radical scavenging and antioxidant properties, on paclitaxel-induced ototoxicity. Materials and Methods: Eighteen male Wistar albino rats were allocated into three groups of six rats at random. No paclitaxel or farnesene was given to the control group throughout the research. Paclitaxel was given four times intraperitoneally at a dose of 5 mg/kg (1st, 7th, 14th & 21st days) in the paclitaxel group. In the Farnesene + Paclitaxel group, 5 mg/kg paclitaxel was given first, followed by 4 times 50 mg/kg farnesene intraperitoneally 30 minutes later (1st, 7th, 14th & 21st days). Otoacoustic emission measurement was taken on days 0 and 21 in all rats. After that, the animals were sacrificed, and their cochleas were extracted for biochemical testing. Results: Paclitaxel caused oxidative stress in the cochlea, which considerably elevated malondialdehyde levels and lowered glutathione levels in cochlear tissues. Furthermore, the paclitaxel group’s distortion product otoacoustic emission values were significantly lower than the other groups. Improvements in the damage produced by paclitaxel in various biochemical and functional parameters were observed in the Farnesene+Paclitaxel group. Conclusion: The study findings imply that farnesene, a natural antioxidant, reduced paclitaxel-induced hearing loss in rats, and a combination of farnesene and paclitaxel therapy may have protected from paclitaxel-induced ototoxicity for future clinical use.
Zingiberene attenuates paclitaxel-induced ototoxicity by strengthening cochlear antioxidant defense system in vivo
(2023-03-15) Büşra DİNÇER; Fatma ATALAY; Arzu TATAR
Paclitaxel is widely used in the treatment of many cancers. Paclitaxel-induced ototoxicity is related to the neurotoxic effects of paclitaxel on auditory peripheral neurons. Zingiberene has significant antitumor and antioxidant properties. This study aimed to determine whether zingiberene protects against the ototoxicity caused by paclitaxel. Twenty-four Wistar Albino rats were divided into four groups. The control group received 1 ml/kg saline on days 1, 7, 14, and 21. The paclitaxel group received 5 mg/kg paclitaxel on days 1, 7, 14, and 21. On days 1, 7, 14, and 21, the zingiberene group received 10mg/kg of zingiberene. Paclitaxel + zingiberene group first 5 mg/kg paclitaxel and 30 minutes later 10mg zingiberene on the 1st, 7th, 14th, and 21st days. A distortion product-evoked otoacoustic emission test (DPOAE) was performed before (day 0) and after (day 22) of the experiment. The pretreatment DPOAE values of the groups were not significantly different. On day 22, the DPOAE results in the paclitaxel group showed a considerable decline. Malondialdehyde levels were substantially higher, and glutathione levels were much lower in the paclitaxel group. The paclitaxel+zingiberene group displayed significantly higher DPOAE levels than the paclitaxel group. Compared to the paclitaxel group paclitaxel+zingiberene, glutathione levels were considerably higher, and malondialdehyde levels were significantly lower. The study findings provide the first evidence in the literature that zingiberene can prevent ototoxicity from paclitaxel-induced hearing loss by lowering the levels of oxidant parameters. It demonstrates that administering zingiberene and paclitaxel together may be a practical clinical approach to alleviate paclitaxel- induced ototoxicity.